10 Best Performing Pharma Stocks in 2025

8. AstraZeneca PLC (NASDAQ:AZN)

1-Year Performance: 42.37%

Number of Hedge Fund Holders: 54

AstraZeneca PLC (NASDAQ:AZN) is one of the best performing pharma stocks in 2025. On January 7, Berenberg Bank reiterated a Buy rating on AstraZeneca PLC (NASDAQ:AZN) with a price target of $95. The rating update came after AstraZeneca PLC (NASDAQ:AZN) announced positive full results from the Phase III TULIP-SC trial on December 6, reporting that the subcutaneous administration of Saphnelo (anifrolumab) exhibited a clinically meaningful and statistically significant drop in disease activity compared to placebo in patients with systemic lupus erythematosus (SLE).

56.2% of patients who received Saphnelo in the TULIP-SC full analysis showed disease activity reduction at Week 52 compared to 37.1% receiving placebo, as measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA), with the results consistent with those from previous trials.

Management further reported that the safety profile observed in the TULIP-SC trial was also consistent with Saphnelo’s known clinical profile, administered as an intravenous (IV) infusion. According to AstraZeneca PLC (NASDAQ:AZN), the full results corroborated the findings from the interim analysis, which was statistically significant.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians.